{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T20:47:20Z","timestamp":1761511640141},"reference-count":24,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2000,4,1]],"date-time":"2000-04-01T00:00:00Z","timestamp":954547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,12,24]],"date-time":"2019-12-24T00:00:00Z","timestamp":1577145600000},"content-version":"vor","delay-in-days":7206,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Annals of Oncology"],"published-print":{"date-parts":[[2000,4]]},"DOI":"10.1023\/a:1008384326701","type":"journal-article","created":{"date-parts":[[2002,12,22]],"date-time":"2002-12-22T14:41:38Z","timestamp":1040568098000},"page":"421-426","source":"Crossref","is-referenced-by-count":19,"title":["A phase I trial of docetaxel and gemcitabine in patients with advanced cancer"],"prefix":"10.1016","volume":"11","author":[{"given":"D.","family":"Rischin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Boyer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Smith","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Millward","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Michael","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Bishop","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Zalcberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Davison","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.","family":"Emmett","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B.","family":"McClure","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1023\/A:1008384326701_bb0005","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1200\/JCO.1994.12.6.1232","article-title":"Phase II trial of docetaxel in patients with stage III and IV non-small-cell lung cancer","volume":"12","author":"Francis","year":"1994","journal-title":"J Clin Oncol"},{"key":"10.1023\/A:1008384326701_bb0010","doi-asserted-by":"crossref","first-page":"1821","DOI":"10.1200\/JCO.1994.12.9.1821","article-title":"Single-agent activity of weekly gemcitabine in advanced non-small-cell lung cancer: A phase II study","volume":"12","author":"Anderson","year":"1994","journal-title":"J Clin Oncol"},{"key":"10.1023\/A:1008384326701_bb0015","doi-asserted-by":"crossref","first-page":"2731","DOI":"10.1200\/JCO.1995.13.11.2731","article-title":"Advanced breast cancer: A phase II trial with gemcitabine","volume":"13","author":"Carmichael","year":"1995","journal-title":"J Clin Oncol"},{"key":"10.1023\/A:1008384326701_bb0020","doi-asserted-by":"crossref","first-page":"2879","DOI":"10.1200\/JCO.1995.13.12.2879","article-title":"Phase II trial of docetaxel in advanced anthracycline-resistant or anthracenedione-resistant breast cancer","volume":"13","author":"Ravdin","year":"1995","journal-title":"J Clin Oncol"},{"key":"10.1023\/A:1008384326701_bb0025","doi-asserted-by":"crossref","first-page":"2403","DOI":"10.1200\/JCO.1997.15.6.2403","article-title":"Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: A randomized trial","volume":"15","author":"Burris HA","year":"1997","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1023\/A:1008384326701_bb0030","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1097\/00001813-199507004-00005","article-title":"Docetaxel delivers new management opportunities for gastrointestinal carcinomas","volume":"6","author":"Rougier","year":"1995","journal-title":"Anti-Cancer Drugs"},{"key":"10.1023\/A:1008384326701_bb0035","doi-asserted-by":"crossref","first-page":"3394","DOI":"10.1200\/JCO.1997.15.11.3394","article-title":"Phase II study of single-agent gemcitabine in previously untreated patients with metastatic urothelial cancer","volume":"15","author":"Stadler","year":"1997","journal-title":"J Clin Oncol"},{"key":"10.1023\/A:1008384326701_bb0040","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1200\/JCO.1997.15.5.1853","article-title":"Phase II trial of docetaxel in patients with advanced or metastatic transitional-cell carcinoma","volume":"15","author":"McCaffrey","year":"1997","journal-title":"J Clin Oncol"},{"key":"10.1023\/A:1008384326701_bb0045","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1006\/gyno.1996.0284","article-title":"Activity of gemcitabine in patients with advanced ovarian cancer: Responses seen following platinum and paclitaxel","volume":"63","author":"Shapiro","year":"1996","journal-title":"Gynecol Oncol"},{"key":"10.1023\/A:1008384326701_bb0050","doi-asserted-by":"crossref","first-page":"2301","DOI":"10.1200\/JCO.1994.12.11.2301","article-title":"Phase II trial of docetaxel in patients with platinum-refractory advanced ovarian cancer","volume":"12","author":"Francis","year":"1994","journal-title":"J Clin Oncol"},{"key":"10.1023\/A:1008384326701_bb0055","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1200\/JCO.1997.15.2.750","article-title":"Phase I trial of docetaxel and cisplatin in previously untreated patients with advanced nonsmall-cell lung cancer","volume":"15","author":"Millward","year":"1997","journal-title":"J Clin Oncol"},{"key":"10.1023\/A:1008384326701_bb0060","doi-asserted-by":"crossref","first-page":"1656","DOI":"10.1200\/JCO.1996.14.5.1656","article-title":"Phase I dose-escalation trial of gemcitabine and cisplatin for advanced non-small-cell lung cancer: Usefulness of mathematic modeling to determine maximum-tolerable dose","volume":"14","author":"Shepherd","year":"1996","journal-title":"J Clin Oncol"},{"key":"10.1023\/A:1008384326701_bb0065","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1200\/JCO.1995.13.3.645","article-title":"Phase II study of docetaxel for advanced or metastatic platinum-refractory non-small-cell lung cancer","volume":"13","author":"Fossella","year":"1995","journal-title":"J Clin Oncol"},{"key":"10.1023\/A:1008384326701_bb0070","first-page":"446a","article-title":"Salvage therapy with gemcitabine in pretreated, advanced non-small-cell lung cancer","volume":"16","author":"Crino","year":"1997","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1023\/A:1008384326701_bb0075","first-page":"148a","article-title":"Phase II study of taxotere, doxorubicin and cyclophosphamide in the treatment of metastatic breast cancer","volume":"16","author":"Nabholtz","year":"1997","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1023\/A:1008384326701_bb0080","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1023\/A:1008377819875","article-title":"Severe pulmonary toxicity in patients treated with a combination of docetaxel and gemcitabine for metastatic transitional cell carcinoma","volume":"10","author":"Dunsford","year":"1999","journal-title":"Ann Oncol"},{"key":"10.1023\/A:1008384326701_bb0085","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1200\/JCO.1999.17.3.914","article-title":"Front-line treatment of advanced non-small-cell lung cancer with docetaxel and gemcitabine: A multicenter phase II trial","volume":"17","author":"Georgoulias","year":"1999","journal-title":"J Clin Oncol"},{"key":"10.1023\/A:1008384326701_bb0090","first-page":"461a","article-title":"Docetaxel plus cisplatin versus docetaxel plus gemcitabine chemotherapy in advanced non-small-cell lung cancer: A preliminary analysis of a multicenter randomized phase II trial","volume":"18","author":"Georgoulias","year":"1999","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1023\/A:1008384326701_bb0095","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1023\/A:1008315723253","article-title":"Salvage chemotherapy in anthracycline-pretreated metastatic breast cancer patients with docetaxel and gemcitabine: A multicenter phase II trial","volume":"10","author":"Mavroudis","year":"1999","journal-title":"Ann Oncol"},{"key":"10.1023\/A:1008384326701_bb0100","doi-asserted-by":"crossref","first-page":"3866","DOI":"10.1200\/JCO.1998.16.12.3866","article-title":"Phase I study of docetaxel dose escalation in combination with fixed weekly gemcitabine in patients with advanced malignancies","volume":"16","author":"Spiridonidis","year":"1998","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1023\/A:1008384326701_bb0105","first-page":"1145","article-title":"A Phase I study of taxotere (T) and gemzar (G) in patients with advanced solid tumors: Impact of drug sequence and feasibility","volume":"35","author":"Dumez","year":"1999","journal-title":"Proc ECCO"},{"issue":"4","key":"10.1023\/A:1008384326701_bb0110","first-page":"1165","article-title":"Gemcitabine and docetaxel in patients with advanced solid tumors. A GETICS phase I trial","volume":"35","author":"Jaremtchuk","year":"1999","journal-title":"Proc ECCO"},{"key":"10.1023\/A:1008384326701_bb0115","first-page":"720","article-title":"Phase I and pharmacokinetic study of docetaxel (DTX) and gemcitabine (G) in patients with non-small-cell lung cancer (NSCLC)","volume":"18","author":"Pujol","year":"1999","journal-title":"Proc ASCO"},{"key":"10.1023\/A:1008384326701_bb0120","first-page":"1924","article-title":"Phase I study of docetaxel and gemcitabine combination chemotherapy in chemotherapy-naive patients with advanced or metastatic non-small-cell lung cancer","volume":"17","author":"Schlosser","year":"1998","journal-title":"Proc ASCO"}],"container-title":["Annals of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419550177?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419550177?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/academic.oup.com\/annonc\/article-pdf\/11\/4\/421\/7296259\/11-4-421.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,2,20]],"date-time":"2020-02-20T07:14:44Z","timestamp":1582182884000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0923753419550177"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2000,4]]},"references-count":24,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2000,4]]}},"alternative-id":["S0923753419550177"],"URL":"https:\/\/doi.org\/10.1023\/a:1008384326701","relation":{},"ISSN":["0923-7534"],"issn-type":[{"value":"0923-7534","type":"print"}],"subject":[],"published":{"date-parts":[[2000,4]]}}}